Atrial Fibrillation News and Research

RSS
Atrial fibrillation (AF) is the most common arrhythmia. An arrhythmia is a problem with the speed or rhythm of the heartbeat. A disorder in the heart’s electrical system causes AF and other types of arrhythmia. AF occurs when rapid, disorganized electrical signals in the heart’s two upper chambers, called the atria, cause them to contract very fast and irregularly (this is called fibrillation). As a result, blood pools in the atria and isn’t pumped completely into the heart’s two lower chambers, called the ventricles. When this happens, the heart’s upper and lower chambers don’t work together as they should. Often, people who have AF may not even feel symptoms. However, even when not noticed, AF can lead to an increased risk of stroke. In many patients, particularly when the rhythm is extremely rapid, AF can cause chest pain, heart attack, or heart failure. AF may occur rarely or every now and then, or it may become a persistent or permanent heart rhythm lasting for years.
Merck to market and develop cardiovascular medicines for a range of cardiovascular disorders

Merck to market and develop cardiovascular medicines for a range of cardiovascular disorders

ARYx Therapeutics announces operating results for the third quarter of 2009

ARYx Therapeutics announces operating results for the third quarter of 2009

New mapping technology to treat patients with heart rhythm disorders

New mapping technology to treat patients with heart rhythm disorders

IntriCon to launch new CDM device at 2009 AHA Scientific Sessions

IntriCon to launch new CDM device at 2009 AHA Scientific Sessions

Cardiome Pharma announces financial results for the three months ended September 30, 2009

Cardiome Pharma announces financial results for the three months ended September 30, 2009

Scientists identify a novel cellular source of atrial fibrillation

Scientists identify a novel cellular source of atrial fibrillation

St. David's Medical Center to use FDA cleared CARTO 3 Navigation System for treating cardiac arrhythmia

St. David's Medical Center to use FDA cleared CARTO 3 Navigation System for treating cardiac arrhythmia

Atrial fibrillation device market will grow by almost 10% through 2013: MRG

Atrial fibrillation device market will grow by almost 10% through 2013: MRG

sanofi-aventis reports financial results for the third quarter of 2009

sanofi-aventis reports financial results for the third quarter of 2009

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

Cardiome Pharmam, Astellas Pharma begin patient enrolment for ACT 5 trial

Cardiome Pharmam, Astellas Pharma begin patient enrolment for ACT 5 trial

NeoChord commences patient enrollment in its TACT European clinical trial

NeoChord commences patient enrollment in its TACT European clinical trial

New CCS guidelines and position papers for physicians and nurse practitioners

New CCS guidelines and position papers for physicians and nurse practitioners

BIOTRONIK launches its new, unified platform pacemaker series in Europe

BIOTRONIK launches its new, unified platform pacemaker series in Europe

St. Jude Medical to repurchase shares of up to $500 million from its outstanding common stock

St. Jude Medical to repurchase shares of up to $500 million from its outstanding common stock

Learn to recognise stroke symptoms and take action: World Stroke Organization

Learn to recognise stroke symptoms and take action: World Stroke Organization

St. Jude Medical announces fiscal 2009 third-quarter results

St. Jude Medical announces fiscal 2009 third-quarter results

New results from ADVANCE provide important insights to reduce diabetes complications

New results from ADVANCE provide important insights to reduce diabetes complications

St. Jude Medical's quadripolar pacing system receives European CE Mark approval

St. Jude Medical's quadripolar pacing system receives European CE Mark approval

Hansen Medical announces its plan to restate its previous financial results

Hansen Medical announces its plan to restate its previous financial results

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.